EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Monotherapy With Immune Checkpoint Inhibitors in Patients With Recurrent and/or Metastatic Sinonasal Squamous Cell Carcinoma

Alexander Lein iD, Thorsten Fuereder, Manuel Stoeth iD, Agmal Scherzad, Stephan Hackenberg, Julia Schnöll iD, Lorenz Kadletz-Wanke, Gregor Heiduschka, Archana Jaiswal, Rajiv Bhalla, Lukas Kenner, Faris F Brkic

Cancer Medicine · 2025

DOI: 10.1002/cam4.71391 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Alexander Lein und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasm Recurrence, Local, Paranasal Sinus Neoplasms, Nivolumab. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sinonasal squamous cell carcinoma (SNSCC) is a rare malignancy with limited data on effective treatment modalities in the recurrent and/or metastatic (r/m) setting. While immune checkpoint inhibitors (ICIs) have shown promise in treating head and neck cancers, in general, their effects in SNSCC remain poorly understood. Furthermore, SNSCC patients are frequently excluded from clinical trials, limiting the evidence base for ICI efficacy in this specific subgroup. Therefore, our study evaluated the efficacy and safety of single‐agent ICI therapy in r/m SNSCC.

Methods

We conducted a retrospective multicenter analysis of all r/m SNSCC patients treated with single‐agent ICIs from July 2018 to December 2023 at two tertiary reference centers.

Results

A total of 18 patients received either Pembrolizumab ( n = 8) or Nivolumab ( n = 10) for r/m SNSCC. The overall response rate (ORR) to immunotherapy was 11.1% (2/18), with a disease control rate (DCR) of 27.8% (5/18) and a mean PFS and OS of 11.7 (95% CI: 2.3–21.0) months and 18.9 (95% CI: 8.3–29.5) months respectively. Two (11.1%) immune‐related adverse events led to treatment discontinuation. Univariable analysis revealed high pathological grading ( p = 0.049) as a negative prognostic factor for PFS. In an exploratory comparison with a larger cohort of 121 patients with r/m SCC of the larynx, oropharynx, hypopharynx, or oral cavity receiving ICI therapy, outcomes in SNSCC appeared broadly similar, with no statistically significant differences in PFS ( p = 0.153), OS ( p = 0.152), ORR ( p = 0.401), or DCR ( p = 0.359).

Conclusion

Immunotherapy may represent a treatment option for patients with SNSCC. Given the limited sample size, these results should be interpreted with caution. Our findings highlight the urgent need to include SNSCC patients in future prospective trials to clarify the role of immunotherapy in this underrepresented population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasm Recurrence, LocalParanasal Sinus NeoplasmsNivolumabCarcinoma, Squamous CellSquamous Cell Carcinoma of Head and NeckHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAntibodies, Monoclonal, HumanizedAged, 80 and overAdult

Stichwörter der Autor:innen

advanced diseasehead and neck cancerimmune‐checkpoint therapysinonasal squamous cell carcinoma

Substanzen

Immune Checkpoint InhibitorspembrolizumabAntibodies, Monoclonal, HumanizedNivolumab

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.
  • Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Würzburg, Würzburg, Germany.
  • Department of Otorhinolaryngology, Manchester University NHS Foundation Trust, Manchester, UK.
  • Department of Otorhinolaryngology, Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, UK.
  • Department of Pathology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Alexander Lein, Manuel Stoeth, Julia Schnöll

Zitieren

APA

Lein, A., Fuereder, T., Stoeth, M., Scherzad, A., Hackenberg, S., Schnöll, J., Kadletz-Wanke, L., Heiduschka, G., Jaiswal, A., Bhalla, R., Kenner, L., & Brkic, F. F. (2025). Monotherapy With Immune Checkpoint Inhibitors in Patients With Recurrent and/or Metastatic Sinonasal Squamous Cell Carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.71391

Vancouver

Lein A, Fuereder T, Stoeth M, Scherzad A, Hackenberg S, Schnöll J, et al. Monotherapy With Immune Checkpoint Inhibitors in Patients With Recurrent and/or Metastatic Sinonasal Squamous Cell Carcinoma. Cancer Medicine. 2025. doi:10.1002/cam4.71391

BibTeX
@article{Lein2025,
  author = {Lein, Alexander and Fuereder, Thorsten and Stoeth, Manuel and Scherzad, Agmal and Hackenberg, Stephan and Schnöll, Julia and Kadletz-Wanke, Lorenz and Heiduschka, Gregor and Jaiswal, Archana and Bhalla, Rajiv and Kenner, Lukas and Brkic, Faris F},
  title = {Monotherapy With Immune Checkpoint Inhibitors in Patients With Recurrent and/or Metastatic Sinonasal Squamous Cell Carcinoma},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71391}
}
Kostenlos starten →